Search clinical trials for: Moderate Plaque Psoriasis

Total 20284 results

Astellas Pharma Inc
Biogen

Completed

A Study to Assess the Efficacy and Safety of Two Dosing Regimens of Alefacept in Subjects Weighing Between 100kg and 150kg With Moderate to Severe Chronic Plaque Psoriasis

Chronic Plaque Psoriasis

United States, Canada
AbbVie (prior sponsor, Abbott)

Completed

Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice

Moderate to Severe Plaque Psoriasis

Czech Republic, Estonia, Hungary, Israel, Romania, Slovakia, Slovenia, Ukraine
Boehringer Ingelheim

Completed

BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis

Psoriasis
Amgen

Completed

Moderate to Severe Plaque Psoriasis With Scalp Involvement

Psoriasis
Promius Pharma, LLC

Completed

Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis

Psoriasis

United States
Taro Pharmaceuticals USA

Completed

Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis

Psoriasis

United States
Genzyme, a Sanofi Company

Completed

A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis

Moderate to Severe Chronic Plaque Psoriasis

United States
Genentech, Inc.

Completed

A Study to Evaluate the Safety of Raptiva in Adults With Plaque Psoriasis Previously Enrolled in Study ACD2600g

Psoriasis
Merck KGaA, Darmstadt, Germany

Terminated

TRUST Study: Raptiva ® in Hand & Foot Psoriasis (TRUST)

Chronic Plaque Psoriasis

Austria
Merck KGaA, Darmstadt, Germany

Terminated

Raptiva in Palm and Sole Psoriasis

Chronic Plaque Psoriasis
EMD Serono

Terminated

Onercept in the Treatment and Re-Treatment of Subjects With Moderate to Severe Plaque Psoriasis

Arthritis, Psoriatic

United States, Canada
Kyowa Kirin Co., Ltd.

Completed

A Phase 2 Clinical Study of KHK4827

Moderate to Severe Plaque Psoriasis

Japan
Novartis Pharmaceuticals

Withdrawn

Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.

Psoriasis
Genentech, Inc.

Completed

A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy

Psoriasis
Centocor Research & Development, Inc.

Completed

A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis (PHOENIX1)

Psoriasis

United States, Belgium, Canada
University of California, San Francisco

Completed

Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis

Psoriasis

United States
Centocor, Inc.

Completed

A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis

Psoriasis

Taiwan, Korea, Republic of
AbbVie (prior sponsor, Abbott)

Completed

Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis

Psoriasis

Mexico
Astellas Pharma Inc
Astellas Pharma Canada, Inc.

Terminated

Assess the Long-term Effectiveness and Safety of Amevive (Alefacept) in Subjects With Moderate to Severe Chronic Plaque Psoriasis (AWARE-2)

Chronic Plaque Psoriasis

Canada
AbbVie (prior sponsor, Abbott)

Completed

A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis

United States, Canada
AbbVie (prior sponsor, Abbott)

Completed

Open Label Continuation Study in Moderate to Severe Psoriasis

Moderate to Severe Plaque Psoriasis

United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Spain, Sweden, Switzerland, United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom
Centocor Research & Development, Inc.

Completed

A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis

Psoriasis

United States, United Kingdom, Germany, Canada, Austria, France, Switzerland
AbbVie (prior sponsor, Abbott)
Paragon Biomedical

Completed

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis

United States
AbbVie (prior sponsor, Abbott)

Completed

Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

United States, Canada
AbbVie (prior sponsor, Abbott)
Paragon Biomedical

Completed

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Moderate to Severe Plaque Psoriasis

United States
Pfizer

Completed

Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

United States, Canada
Forward-Pharma GmbH

Completed

Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

Germany
Derm Research, PLLC
Genentech, Inc.

Terminated

Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva)

Plaque Psoriasis

United States
Abbott
Assign Data Management and Biostatistics GmbH

Completed

Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying Anti-rheumatic Drugs (QUALITY)

Psoriasis Chronic

Austria
Pfizer

Completed

Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis (PRISTINE)

Psoriasis | Plaque Psoriasis

Spain, Taiwan, Germany, Korea, Republic of, Belgium, Greece, Hungary, Argentina, Austria, Czech Republic, Italy, Mexico, Thailand
Biotest

Completed

Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis Vulgaris

Czech Republic, Hungary
Innovaderm Research Inc.
Abbott; Montreal Heart Institute

Completed

Effect of Adalimumab on Vascular Inflammation in Patients With Moderate to Severe Plaque Psoriasis

Psoriasis | Coronary Atherosclerosis | Vascular Inflammation

Canada
Abbott

Withdrawn

Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.

Moderate to Severe Plaque Psoriasis
Stiefel, a GSK Company

Completed

An Open-Label, Multi-Center Trial in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis

Psoriasis

Netherlands
Abbott

Completed

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

United States, Austria, Belgium, Canada, France, Germany, Poland, Puerto Rico, Spain, Switzerland
Abbott

Completed

Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (BELIEVE)

Chronic Plaque Psoriasis

Belgium, Denmark, France, Germany, Spain, Sweden, Switzerland, Finland, Turkey, Italy, Czech Republic, Austria, Netherlands, United Kingdom, Greece
Probity Medical Research

Completed

Treatment of Mild to Moderate Joint Pain in Patients With Chronic Plaque Psoriasis Receiving Efalizumab

Arthritis | Arthralgia

Canada
NeoStrata Company, Inc.

Completed

LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis

Chronic Plaque Psoriasis

United States
Manhattan Pharmaceuticals
Therapeutics, Inc.

Completed

A Safety and Efficacy Study of a Topical Gel for the Treatment of Mild to Moderate Psoriasis

Psoriasis Vulgaris

United States
Abbott

Completed

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis (CHAMPION)

Psoriasis

United States
Abbott

Completed

Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Abbott

Completed

Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Abbott

Completed

Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Abbott

Completed

Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Abbott
Eisai Limited

Completed

Adalimumab in Adult Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

Japan
Abbott

Completed

Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Universita di Verona

Completed

Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial

Obesity | Chronic Plaque Psoriasis

Italy
Derm Research, PLLC
Genentech, Inc.; Dermatology Associates, PLLC

Completed

A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis

Plaque Psoriasis

United States
Genentech, Inc.

Completed

A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis

Plaque Psoriasis

3

Subscribe